SCHEMBL23217676

SCHEMBL23217676

CCOC(=O)Cc1ccccc1OC(CC(=O)OC(C)(C)C)c1cc(Br)c2occc2c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.35
HPGD P15428 2/20 0.32
TBXAS1 P24557 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MTNR1A P48039 3/20 0.32
MTNR1B P49286 3/20 0.32
CFD P00746 5/20 0.32
PKM P14618 1/20 0.31
ITGA4 P13612 1/20 0.31
ITGB7 P26010 1/20 0.31
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217814 0.90 CFD (0.36) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
SCHEMBL30010562 0.87 TBXAS1 (0.33) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
SCHEMBL23217830 0.85 CFD (0.45) L3MBTL1CFD
SCHEMBL23217611 0.84 TBXAS1 (0.38) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
SCHEMBL30010940 0.84 TBXAS1 (0.38) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
SCHEMBL29672991 0.83 HPGD (0.40) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
SCHEMBL23217708 0.83 HPGD (0.40) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
Hexane SCHEMBL23217870 0.80 HPGD (0.38) L3MBTL1HPGDTBXAS1KDM4EALDH1A1
SCHEMBL23217579 0.75 CFD (0.51) CFD
SCHEMBL21438395 0.74 CFD (0.52) TBXAS1CFDPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB L3MBTL1 4688/4885HPGD 336/4885TBXAS1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.